目的 探討不同劑型紫杉醇聯(lián)合卡鉑對復(fù)發(fā)性卵巢癌患者的成本-效果。方法 選取滁州市第一人民醫(yī)院2016年5月—2018年5月收治的60例復(fù)發(fā)性卵巢癌患者為研究對象，隨機將其分為對照組與觀察組，每組30例。對照組患者第1日給予175 mg/m²的傳統(tǒng)紫杉醇注射液，加入到5%葡萄糖注射液500 mL中，靜脈滴注3 h，給藥前給予地塞米松預(yù)處理。次日采用5 AUC卡鉑注射液，加入5%葡萄糖注射液500 mL，靜脈滴注2 h。觀察組患者給予175 mg/m²注射用紫杉醇脂質(zhì)體，加入5%葡萄糖注射液500 mL，靜脈滴注3 h；5 AUC卡鉑注射液加入到5%葡萄糖注射液500 mL中，靜脈滴注2 h。21 d為1個周期，兩組共治療6個周期。結(jié)果 治療后，觀察組臨床總有效率為66.67%，與對照組的60.00%相比，差異不具有統(tǒng)計學(xué)意義。治療期間，觀察組患者的毒副反應(yīng)率為20.00%，顯著低于對照組46.67%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。觀察組的化療藥物使用費用高于對照組，毒副反應(yīng)治療藥物低于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。觀察組的增量成本-效果比（△C/△E）為7 234.65，即增加1個效果單位，觀察組需多花7 234.65元。結(jié)論 復(fù)發(fā)性卵巢癌患者采用傳統(tǒng)紫杉醇聯(lián)合卡鉑治療具有較高的療效及經(jīng)濟性，值得臨床推廣應(yīng)用。

Objective To investigate the cost-effectiveness of paclitaxel combined with carboplatin in patients with recurrent ovarian cancer. Methods Patients (60 cases) with recurrent ovarian cancer in the First People's Hospital of Chuzhou from May 2016 to May 2018 were selected as the study subjects, and randomly divided into control group and observation group, with 30 patients in each group. Patients in the control group were given Paclitaxel Injection of 175 mg/m² on the first day, added into 5% glucose injection 500 mL, intravenous infusion for 3 h, and dexamethasone pretreatment before administration. The next day, 5 AUC Carboplatin Injection was added into 5% glucose injection 500 mL, and intravenous infusion was given for 2 hours. Patients in the observation group were given Paclitaxel Liposome for injection 175 mg/m², 500 mL 5% glucose injection was added, and intravenous infusion was administered for 3 h. 5 AUC Carboplatin Injection was added into 5% glucose injection 500 mL, and intravenous infusion was administered for 2 h. 21 d as one cycle, two groups were treated for 6 cycles. Results After treatment, the total clinical effective rate in the observation group was 66.67%, which was not statistically significant compared with 60.00% in the control group. During the treatment, the toxic and side reaction rate in the observation group was 20.00%, which was significantly lower than 46.67% in the control group, the difference between two groups was statistically significant (P<0.05). The use cost of chemotherapy drugs in the observation group was higher than that in the control group, and the toxic and side reaction drugs were lower than that in the control group, the difference between two groups was statistically significant (P<0.05). The △C/△E of the observation group was 7 234.65, that is to say, an additional effect unit was needed, the observation group needed to spend 7 234.65 yuan more. Conclusion Traditional Paclitaxel Injection combined with carboplatin in treatment of recurrent ovarian cancer has high efficacy and economy, which is worthy of clinical application.

R979.1

安徽省衛(wèi)生和計劃生育委員會科研計劃項目（2016QK037）